| abstract |
This invention relates to peptides and peptidomimetic compounds that modulate the function of G-protein-coupled receptors by affecting the ratio of receptor monomer to homo-oligomeric forms. Novel short peptides of a preferred length of up to about 15-20 amino acid residues are modeled on transmembrane domains of G-protein-coupled receptors, whose activities are affected by the formation of oligomers. These novel peptides and peptidomimetic compounds can be used to selectively affect the activity of G-protein-coupling receptors, thereby functioning as potential therapeutic drugs, etc.. A preferred peptide is GIIMGTFTLCWLPFFIVNIV. |